Marrow mesenchymal stromal cells reduce methicillin-resistant Staphylococcus aureus infection in rat models

Cytotherapy

Volumn 16, Issue 1, 2014, Pages 56-63

  Yuan, Yuan ^a   lin, Songyi ^a   Guo, Na ^a   Zhao, Chengcheng ^a   Shen, Suxia ^a   Bu, Xiujuan ^a   Ye, Haiqing ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Mesenchymal stromal cells; Methicillin resistant Staphylococcus aureus; Rat models

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; RANTES;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIUM COLONY; BONE MARROW DERIVED MESENCHYMAL STROMAL CELL; CELL THERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; INFECTION CONTROL; MESENCHYMAL STROMA CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WOUND HEALING;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; RATTUS; STAPHYLOCOCCUS;

MESENCHYMAL STROMAL CELLS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RAT MODELS;

ANIMALS; BONE MARROW CELLS; CARBOXYMETHYLCELLULOSE SODIUM; CELL- AND TISSUE-BASED THERAPY; DISEASE MODELS, ANIMAL; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RATS; STAPHYLOCOCCAL INFECTIONS;

EID: 84890982273     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.06.002     Document Type: Article

References (35)

1. Mermel L.A., Farr B.M., Sherertz R.J., Raad I., O'Grady N., Harris J.S., et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001, 32:1249-1272.
2. Yarwood J.M., Bartels D.J., Volper E.M., Greenberg E.P. Quorum sensing in Staphylococcus aureus biofilms. JBacteriol 2004, 186:1838-1850.
3. Haddadin A., Fappiano S., Lipsett P. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J 2002, 78:385-392.
4. Schrock J., Laskey S., Cydulka R. Predicting observation unit treatment failures in patients with skin and soft tissue infections. Int J Emerg Med 2008, 1:85-90.
5. Smith T.L., Pearson M.L., Wilcox K.R., Cruz C., Lancaster M.V., Robinson D.B., et al. Emergence of vancomycin resistance in Staphylococcus aureus. NEngl J Med 1999, 340:493-501.
6. Horwitz E.M., Le Blanc K., Dominici M., Mueller I., Slaper-Cortenbach I., Marini F.C., et al. Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. Cytotherapy 2005, 7:393-395.
7. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the international society for cellular therapy position statement. Cytotherapy 2006, 8:315-317.
8. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74.
9. Friedenstein A.J., Gorskaja J.F., Kulagina N.N. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976, 4:267-274.
10. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
11. Wakitani S., Saito T., Caplan A.I. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 1995, 18:1417-1426.
12. Woodbury D., Schwarz E.J., Prockop D.J., Black I.B. Adult rat and human bone marrow stromal cells differentiate into neurons. Neurosci Res 2000, 61:364-370.
13. Baksh D., Song L., Tuan R.S. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. Cell Mol Med 2004, 8:301-316.
14. Barry F.P., Murphy J.M. Mesenchymal stem cells: clinical applications and biological characterization. Biochem Cell Biol 2004, 36:568-584.
15. Dominici M., Hofmann T.J., Horwitz E.M. Bone marrow mesenchymal cells: biological properties and clinical applications. Biol Regul Homeost Agents 2001, 15:28-37.
16. Horwitz E.M. Stem cell plasticity: the growing potential of cellular therapy. Arch Med Res 2003, 34:600-606.
17. Koc O.N., Lazarus H.M. Mesenchymal stem cells: heading into the clinic. Bone Marrow Transpl 2001, 27:235-239.
18. Stagg J. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens 2007, 69:1-9.
19. Brandau S., Mark J., Hatim H., Kirsten B., Sandra J., Friedrich B., et al. Tissue-resident mesenchymal stem cells attract peripheral blood neutrophils and enhance their inflammatory activity in response to microbial challenge. JLeukocyte Biol 2010, 88:1005-1015.
20. Mei S.H., Haitsma J.J., Dos Santos C.C., Deng Y., Lai P.F., Slutsky A.S., et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010, 182:1047-1057.
21. Yasuda H., Koga T., Fukuda T. In vitro and in vivo models of bacterial biofilms. Methods Enzymol 1999, 310:577-584.
22. Kang X.Q., Zang W.J., Song T.S., Xu X.L., Yu X.J., Li D.L., et al. Rat bone marrow mesenchymal stem cells differentiate into hepatocytes in vitro. World J Castroenterol 2005, 11:3479-3484.
23. Mansilla E., Marin G.H., Sturla F., Drago H.E., Gil M.A., Salas E., et al. Human mesenchymal stem cells are tolerized by mice and improve skin and spinal cord injuries. Transplant Proc 2005, 37:292-294.
24. Morikawa K., Nonaka M., Yoshikawa Y., Ikuko T. Synergistic effect of fosfomycin and arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm in a rat model. Int J Antimicrob Agents 2005, 25:44-50.
25. Wang D.C., Yu L., Xiang H., Fan J.W., He L., Guo N., et al. Global transcriptional profiles of Staphylococcus aureus treated with berberine chloride. Fems Microbiol Lett 2008, 279:217-225.
26. Anokhina E.B., Buravkova L.B. Heterogeneity of stromal precursor cells isolated from rat bone marrow. Tsitologiia 2007, 49:40-47.
27. Németh K., Leelahavanichkul A., Yuen P.S., Mayer B., Parmelee A., Doi K., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E-2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009, 15:42-49.
28. Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 2008;76:4176-82.
29. Singh P.K., Parsek M.R., Greenberg E.P., Welsh M.J. Acomponent of innate immunity prevents bacterial biofilm development. Nature 2002, 417:552-555.
30. Krasnodembskaya A., Song Y., Fang X., Gupta N., Serikov V., Lee J., et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010, 28:2229-2238.
31. Chamberlain G., Fox J., Ashton B., Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007, 25:2739-2749.
32. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
33. van Laar J.M., Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology 2006, 45:1187-1193.
34. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 2006, 312:2169-2179.
35. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.